KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321.

Shuhua Yi, Jiang Cao, Ru Feng, Keshu Zhou, Lihua Qiu, Fei Li, Hai Yan Yang, Hui Zhou, Wuhan Hui, Jie Cui, He Huang, Jiankun Zhu, Xiuhui Ye, Jeff Sharman, Lugui Qiu

Br J Haematol 208(3) 926-936

PMID41571607
PMCIDPMC12995541
DOI10.1111/bjh.70334
发表日期2026-01-22
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BRUIN CLL-321 is the first prospective, randomized study conducted in covalent BTK inhibitor (cBTKi) pretreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) patients. In this heavily pretreated population, pirtobrutinib significantly improved progression-free survival (PFS) compared to investigator's choice (IC) of idelalisib/rituximab (IdelaR) or bendamustine/rituximab (BendaR). This report presents results from Chinese patients enrolled in BRUIN CLL-321, who were randomized 1:1 to pirtobrutinib (200 mg once daily) or IC of BendaR (idelalisib is not approved in China). End-points included independent review committee (IRC)-assessed PFS, investigator (INV)-assessed PFS, overall survival (OS), event-free survival (EFS), time to next treatment (TTNT) and safety. Among 40 Chinese patients (pirtobrutinib n = 19; BendaR n = 21), IRC-assessed PFS favoured pirtobrutinib (stratified hazard ratio [HR] = 0.281; 95% confidence interval [CI], 0.070-1.125, nominal p = 0.0554), with median PFS not reached versus 10.6 months with BendaR; INV-assessed PFS supported these findings. TTNT (HR = 0.150; 95% CI, 0.031-0.728) and EFS (HR = 0.322; 95% CI, 0.094-1.101) were also improved. A trend towards OS benefit was observed (HR = 0.343; 95% CI, 0.031-3.787). Pirtobrutinib showed a favourable safety profile, with fewer grade ≥3 treatment-emergent adverse events (36.8% vs. 93.3%) and serious adverse events (15.8% vs. 46.7%). These findings support pirtobrutinib as a clinically active and tolerable option for cBTKi-pretreated Chinese CLL/SLL population.

KM 提取结果

4 个 Figure · 5 个 KM 面板

进入结果中心
KM Figure2 个面板

FIGURE 2

FIGURE 2 Kaplan–Meier curve of PFS as assessed by (A) IRC and (B) Investigator. HR, based on the stratified Cox proportional hazards model, with stratification factors: Deletion 17p presence and receipt of prior venetoclax treatment. Two‐sided p ‐value is based on the stratified log‐rank test for comparing pirtobrutinib versus BendaR. BendaR, bendamustine+rituximab; CI, confidence interval; HR, hazard ratio; IRC, independent review committee; NR, not reached; PFS, progression‐free survival.

A

Progression-free survival (IRC)

FIGURE 2 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 2:extreme jump曲线 2:off origin start曲线 2:extreme upward reversal
查看结果
B

Progression-free survival (Investigator)

FIGURE 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:extreme jump
查看结果
KM Figure1 个面板

FIGURE 3

FIGURE 3 Kaplan–Meier curve of overall survival. HR, based on the stratified Cox proportional hazards model, with stratification factors: Deletion 17p presence and receipt of prior venetoclax treatment. Two‐sided p ‐value is based on the stratified log‐rank test for comparing pirtobrutinib versus BendaR. BendaR, bendamustine+rituximab; CI, confidence interval; HR, hazard ratio; NR, not reached.

Overall_survival

Overall survival

FIGURE 3 · Panel Overall_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Overall_survival 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

FIGURE 4

FIGURE 4 Kaplan–Meier curve of time to next treatment. HR, based on the stratified Cox proportional hazards model, with stratification factors: Deletion 17p presence and receipt of prior venetoclax treatment. Two‐sided p ‐value is based on the stratified log‐rank test for comparing pirtobrutinib versus BendaR. BendaR, bendamustine+rituximab; CI, confidence interval; HR, hazard ratio; NR, not reached.

Time_to_next_treatment

time to next treatment

FIGURE 4 · Panel Time_to_next_treatment

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Time_to_next_treatment 是同一 FIGURE 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:off origin start
查看结果
KM Figure1 个面板

FIGURE 5

FIGURE 5 Kaplan–Meier curve of event‐free survival. HR, based on the stratified Cox proportional hazards model, with stratification factors: Deletion 17p presence and receipt of prior venetoclax treatment. Two‐sided p ‐value is based on the stratified log‐rank test for comparing pirtobrutinib versus BendaR. BendaR, bendamustine+rituximab; CI, confidence interval; HR, hazard ratio; NR, not reached.

Event-free_survival_curve

Event-free survival

FIGURE 5 · Panel Event-free_survival_curve

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Event-free_survival_curve 是同一 FIGURE 5 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 2:extreme jump曲线 2:off origin start曲线 2:extreme upward reversal
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Study design schema for Chinese population. Treatment was given in 28‐day cycles. PFS assessed based on iwCLL 2018. a Bendamustine (70 mg/m 2 ) administered IV on Day 1, Day 2 of cycles 1–6. b Rituximab, first dose at 375 mg/m 2 IV on Day 1 of cycle 1, then next five infusions at 500 mg/m 2 on Day 1 of Cycles 2–6. c Since Idelalisib has not been approved in China, Chinese investigators could only choose the BendaR regimen as IC for patients in this treatment arm. d Eligible patients receiving investigator's choice of BendaR could crossover to receive pirtobrutinib monotherapy upon confirmation of PD by IRC per protocol. BendaR, bendamustine+rituximab; cBTKi, covalent BTK inhibitor; CLL, chronic lymphocytic leukaemia; ECOG PS, Eastern Cooperative Oncology Group performance status; IC, Investigator's choice; IRC, independent review committee; IV, intravenous; iwCLL, international workshop on CLL; PD, progression disease; PFS, progression‐free survival; PO, by mouth; QD, once daily; R, randomized; SLL, small lymphocytic lymphoma.
非 KM Figure